Evaluation of the effect of Ivermectin in treatment of outpatients with COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19 infection.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20111224008507N4
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Patients with positive coronavirus rapid test or RT-PCR positive
No need for hospitalization
Weight >15 kg
Age >5 years
No treatment with antiviral drugs before and during the study
Informed consent for inclusion
Exclusion Criteria
Underlying liver and kidney disease
Patients with acquired immunodeficiency
Pregnancy and lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical improvement. Timepoint: Daily until improvement. Method of measurement: Clinical improvement is defined as reduction in persistent cough (more than one hour of excessive coughing, or 3 periods of coughing in 24 hours that disrupts daily life and ability to work) and tachypnea and O2 saturation above 94%.;Negative PCR result. Timepoint: 6 days after intervention. Method of measurement: RT-PCR.
- Secondary Outcome Measures
Name Time Method The main complaints recovery time. Timepoint: Daily until symptoms resolve. Method of measurement: Checklist containing patient complaints.;Need to be hospitalized. Timepoint: Daily until hospitalization or improvement. Method of measurement: Percentage of hospitalization and the interval from the beginning of the intervention to hospitalization.;Mortality. Timepoint: Daily. Method of measurement: Record in checklist.;Drug side effect. Timepoint: Daily. Method of measurement: Wheezing, itching, skin rash, edema, and hypotension are assessed daily.